Department of Acute Infection, Ningbo No. 2 Hospital Ningbo, Zhejiang, China.
Eur Rev Med Pharmacol Sci. 2017 Apr;21(8):1738-1745.
To discuss the influences of radiofrequency ablation (RFA) combined with hepatic arterial chemoembolization on the expression level of immunity and hypoxia-inducible factor (HIF-1a) and early growth response protein2 (EGR2) of patients with hepatocarcinoma.
Patients with primary hepatic carcinoma treated in our hospital from 2011 to 2014 were divided into research group (RFA+TACE) and control group (TACE) according to different therapy methods, with 72 patients in each group. Then, the immunity functions were detected before treatment and 3 months after treatment, the expression level of HIF-1a, EGR-2, the alpha fetal protein (AFP), the therapeutic effect, and incidence of adverse reaction in near and specific future were compared between two groups.
After treatment, the ratio of CD3+ and CD4+T cells, specific vale of CD4/CD8, and NK cell population in research group were more than those in control group, while the ratio of CD8+T cells was less than that in control group with statistical significance. Meanwhile, the expression levels of HIF-1a (F between-grouptime point = 5.353, p = 0.043), EGR-2 (F between-grouptime point = 4.385, p = 0.044), and AFP (F between-group*time point = 4.205, p = 0.045) had difference with statistical significance. Moreover, the recent therapy response rate in research group was 76.4%, which was higher than that in control group (50.0%), with significant difference (χ2 = 10.784, p = 0.029), while the difference of long-term therapeutic effect between two groups has statistical significance (χ2 = 7.439, p = 0.005).
The treatment of primary hepatic carcinoma by TACE combined with RAF therapeutic schedule was helpful in improving organic immunity, decreasing tumor angiogenesis and reducing tumor cell proliferation speed to improve the short- and long-term therapeutic effects.
探讨射频消融（RFA）联合肝动脉化疗栓塞（TACE）对肝癌患者免疫功能及缺氧诱导因子（HIF-1a）和早期生长反应蛋白 2（EGR2）表达水平的影响。
选取 2011 年至 2014 年我院收治的原发性肝癌患者，根据治疗方法的不同分为研究组（RFA+TACE）和对照组（TACE），每组 72 例。然后，分别于治疗前和治疗后 3 个月检测患者的免疫功能，比较两组患者 HIF-1a、EGR-2、甲胎蛋白（AFP）的表达水平、近期及远期疗效及不良反应发生率。
治疗后，研究组患者 CD3+、CD4+T 细胞比值、CD4/CD8 比值及 NK 细胞比例均高于对照组，CD8+T 细胞比值低于对照组，差异均有统计学意义（F 值分别为 5.353、4.385、4.205，p 值分别为 0.043、0.044、0.045）。同时，两组患者 HIF-1a（F 组间时间点=5.353，p=0.043）、EGR-2（F 组间时间点=4.385，p=0.044）和 AFP（F 组间*时间点=4.205，p=0.045）的表达水平均有差异。此外，研究组近期治疗有效率为 76.4%，高于对照组的 50.0%，差异有统计学意义（χ2=10.784，p=0.029），而两组远期疗效差异有统计学意义（χ2=7.439，p=0.005）。
TACE 联合 RFA 治疗原发性肝癌有助于提高机体免疫功能，降低肿瘤血管生成，减缓肿瘤细胞增殖速度，从而提高近期和远期疗效。
